產(chǎn)品詳情
簡單介紹：
重組人表皮生長因子蛋白與其它公司提供的重組蛋白不同，rHuEGF蛋白產(chǎn)品為采用CFS的無細胞麥胚蛋白合成系統(tǒng)表達出來的重組蛋白，可表達出對細胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時獨有的全自動蛋白純化技術(shù)則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組人表皮生長因子蛋白（全長序列）產(chǎn)品可用于Western Blot驗證、抗體制備、蛋白檢測、ELISA等試驗中.
詳情介紹：
重組人表皮生長因子蛋白
| Synonyms | Urogastrone, URG |
| Species | Human |
| Accession | P01133 |
| Unigene | Hs.419815. |
| Source | Escherichia coli. |
| Molecular Weight | Approximately 6.2 kDa, a single non-glycosylated polypeptide chain containing 53 amino acids. |
| Quantity | 100μg/500μg/1000μg |
| AA Sequence | NSDSECPLSH DGYCLHDGVC MYIEALDKYA CNCVVGYIGE RCQYRDLKWW ELR |
| Purity | > 98 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人表皮生長因子蛋白Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine Balb/c 3T3 cells is less than 0.1 ng/ml, corresponding to a specific activity of > 1.0 × 107 IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | Less than 1 EU/μg of rHuEGF as determined by LAL method. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
|
|
重組人表皮生長因子蛋白 |
| SDS-PAGE |
|
| Reference |
重組人表皮生長因子蛋白1. Chevalier RL, Goyal S, Thornhill BA. 1999. J Urol, 162: 1532-6. 2. Gehm BD, McAndrews JM, Jordan VC, et al. 2000. Mol Cell Endocrinol, 159: 53-62. 3. Yang H, Sun X, Wang Z, et al. 2003. J Membr Biol, 194: 47-58. 4. Cohen S. 2008. J Biol Chem, 283: 33793-7. |
| Background | Epidermal Growth Factor (EGF) was originally discovered in crude preparations of nerve growth factor prepared from mouse submaxillary glands as an activity that induced early eyelid opening, incisor eruption, hair growth inhibition, and stunting of growth when injected into newborn mice. Human EGF was isolated from urine based on its inhibitory effect on gastric secretion and named urogastrone, accordingly. EGF is prototypic of a family of growth factors that are derived from membrane-anchored precursors. 重組人表皮生長因子蛋白All members of this family are characterized by the presence of at least one EGF structural unit (defined by the presence of a conserved 6 cysteine motif that forms three disulfide bonds) in their extracellular domain. EGF is initially synthesized as a 130 kDa precursor transmembrane protein containing 9 EGF units. The mature soluble EGF sequence corresponds to the EGF unit located proximal to the transmembrane domain. The membrane EGF precursor is capable of binding to the EGF receptor and was reported to be biologically active. Mature human EGF shares 70 % a.a. sequence identity with mature mouse and rat EGF. |
